Abstract
Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.
| Original language | English |
|---|---|
| Pages (from-to) | 3707-3711 |
| Number of pages | 5 |
| Journal | Anticancer research |
| Volume | 38 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer. / Toyokawa, Gouji; Takada, Kazuki; Tagawa, Tetsuzo; Kinoshita, Fumihiko; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Takamori, Shinkichi; Akamine, Takaki; Hirai, Fumihiko; Yamada, Yuichi; Hamamoto, Ryuji; Oda, Yoshinao; Maehara, Yoshihiko.
In: Anticancer research, Vol. 38, No. 6, 01.06.2018, p. 3707-3711.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevalence of enhancer of zeste homolog 2 in patients with resected small cell lung cancer
AU - Toyokawa, Gouji
AU - Takada, Kazuki
AU - Tagawa, Tetsuzo
AU - Kinoshita, Fumihiko
AU - Kozuma, Yuka
AU - Matsubara, Taichi
AU - Haratake, Naoki
AU - Takamori, Shinkichi
AU - Akamine, Takaki
AU - Hirai, Fumihiko
AU - Yamada, Yuichi
AU - Hamamoto, Ryuji
AU - Oda, Yoshinao
AU - Maehara, Yoshihiko
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.
AB - Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in cancer pathogenesis. Although clinicopathological significance of EZH2 in non-small cell lung cancer has been gradually elucidated, such significance in small cell lung cancer (SCLC) has yet to be fully investigated. Patients and Methods: Forty patients with resected SCLC were analyzed for EZH2. EZH2 expression was evaluated using the Allred score (0-8) and was classified into negative (0-6) and positive (7 and 8). We evaluated the association between EZH2 and the clinicopathological characteristics and postoperative survivals. Results: Among 40 patients, 15 (37.5%) and 25 (62.5%) were classified as being negative and positive for EZH2, respectively. Fisher’s exact test demonstrated no significant associations between the positivity for EZH2 and clinicopathological characteristics. No significant differences were observed in recurrence-free and overall survivals between EZH2-negative/low and EZH2-high patients. Conclusion: EZH2 was frequently observed in patients with resected SCLC, but no significant associations were found between its expression and the clinicopathological characteristics and postoperative survivals.
UR - http://www.scopus.com/inward/record.url?scp=85048221056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048221056&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12649
DO - 10.21873/anticanres.12649
M3 - Article
C2 - 29848731
AN - SCOPUS:85048221056
VL - 38
SP - 3707
EP - 3711
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 6
ER -